STREPSILS COOL N/A Lozenges

Երկիր: Իռլանդիա

Լեզու: անգլերեն

Աղբյուրը: HPRA (Health Products Regulatory Authority)

Ակտիվ բաղադրիչ:

AMYLMETACRESOL, DICHLOROBENZYL ALCOHOL

Հասանելի է:

Reckitt Benckiser Ireland Ltd

ATC կոդը:

R02AA03

INN (Միջազգային անվանումը):

AMYLMETACRESOL, DICHLOROBENZYL ALCOHOL

Դոզան:

N/A

Դեղագործական ձեւ:

Lozenges

Ռեկվիզորի տեսակը:

Product not subject to medical prescription

Թերապեւտիկ տարածք:

Antiseptics

Լիազորման կարգավիճակը:

Authorised

Հաստատման ամսաթիվը:

2007-02-23

Ապրանքի հատկությունները

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Strepsils Cool Lozenges
2,4-Dichlorobenzyl Alcohol 1.2mg
Amylmetacresol 0.6mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each lozenge contains:
2, 4-Dichlorobenzyl alcohol
1.2 mg
Amylmetacresol
0.6 mg
Excipients: Each lozenge also contains 1.4g sucrose and 1.1g glucose.
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Lozenge
White to pale yellow coloured Lozenge with a characteristic taste of
cool mint, embossed on both sides with Strepsils
brand icon.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the symptomatic relief of mouth and throat infections.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The lowest effective dose should be used for the shortest duration
necessary to retrieve symptoms.
It is recommended
that the product should be used for a maximum of 3 days.
Adults: One lozenge every 2-3 hours. No more than 12 lozenges per day.
Elderly: There is no need for dosage reduction in the elderly.
Paediatric population: Children 12 years and over: One lozenge every
2-3 hours.
No more than 8 lozenges per day.
Children under 12 years: Not suitable for children under 12 years.
Method of administration
For oromucosal administration.
To be dissolved slowly in the mouth.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substances or to any of the excipients
listed in section 6.1.
Patients with rare hereditary problems of fructose intolerance,
glucose-glalctose malabsorption or sucrose-isomaltose
insufficiency should not take this medicine.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_